Variables Affecting CA15.3 Tumor Antigen Expression and Antibodies against It in Female National Health and Nutritional Survey Participants
- PMID: 38864844
- PMCID: PMC11371522
- DOI: 10.1158/1055-9965.EPI-24-0187
Variables Affecting CA15.3 Tumor Antigen Expression and Antibodies against It in Female National Health and Nutritional Survey Participants
Abstract
Background: Cancers of ductal origin often express glycoprotein mucin 1 (MUC1), also known as CA15.3, with higher levels leading to poor prognosis. Conversely, anti-MUC1 antibodies develop in some patients, leading to better prognosis. We sought to identify epidemiologic factors associated with CA15.3 antigen or antibody levels.
Methods: Levels of CA15.3 antigen and anti-CA15.3 IgG antibodies were measured in archived sera from 2,302 mostly healthy women from the National Health and Nutritional Survey; and epidemiologic predictors of their levels were examined using multivariate and correlational analyses.
Results: Among racial groups, Black women had the highest levels of CA15.3 antigen and lowest levels of antibodies. Increasing body mass index and current smoking were associated with low anti-CA15.3 antibody levels. Low CA15.3 antigen levels were seen in oral contraceptive users and high levels in women who were pregnant or lactating at the time of blood collection, with the latter group also having high antibody levels. Past reproductive events associated with high antigen levels included the following: later age at menarche, having given birth, and history of endometriosis. Lower antigen levels were seen with increasing duration of OC use. Anti-CA15.3 antibody levels decreased with an increasing estimated number of ovulatory years.
Conclusions: Key determinants of CA.15.3 antigen or antibody levels include the following: race, body mass index, smoking, later menarche, childbirth, number of ovulatory cycles, and endometriosis.
Impact: This study supports the premise that known epidemiologic factors affecting risk for or survival after MUC1-expressing cancers may, at least partially, operate through their association with CA15.3 antigen or antibody levels.
©2024 American Association for Cancer Research.
Similar articles
-
Racial/ethnic differences in average CA125 and CA15.3 values and its correlates among postmenopausal women in the USA.Cancer Causes Control. 2021 Mar;32(3):299-309. doi: 10.1007/s10552-020-01384-z. Epub 2021 Jan 18. Cancer Causes Control. 2021. PMID: 33462738 Free PMC article.
-
Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort.Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):790-804. doi: 10.1158/1055-9965.EPI-17-0744. Epub 2018 Apr 16. Cancer Epidemiol Biomarkers Prev. 2018. PMID: 29661801 Free PMC article.
-
Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.Anticancer Res. 2012 May;32(5):2185-9. Anticancer Res. 2012. PMID: 22593508
-
Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis.Med Sci Monit. 2016 Sep 6;22:3154-62. doi: 10.12659/msm.896563. Med Sci Monit. 2016. PMID: 27596019 Free PMC article.
-
Clinical Use and Optimal Cutoff Value of Ca15-3 in Evaluation of Adnexal Mass: Retrospective Cohort Study and Review of the Literature.Am J Clin Oncol. 2018 Sep;41(9):838-844. doi: 10.1097/COC.0000000000000383. Am J Clin Oncol. 2018. PMID: 28338481 Review.
References
-
- von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RH, Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers. 2000;154:343–56. - PubMed
-
- Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer. 2003;1031:97–100. - PubMed
-
- Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med. 2000;1612 Pt 1:589–94. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous